Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Cash from Financing Activities: 2013-2024

Historic Cash from Financing Activities for Zevra Therapeutics (ZVRA) over the last 12 years, with Dec 2024 value amounting to $82.1 million.

  • Zevra Therapeutics' Cash from Financing Activities fell 89.92% to $6.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.3 million, marking a year-over-year decrease of 88.05%. This contributed to the annual value of $82.1 million for FY2024, which is 188.46% up from last year.
  • As of FY2024, Zevra Therapeutics' Cash from Financing Activities stood at $82.1 million, which was up 188.46% from $28.5 million recorded in FY2023.
  • In the past 5 years, Zevra Therapeutics' Cash from Financing Activities ranged from a high of $113.1 million in FY2021 and a low of $2.7 million during FY2020.
  • In the last 3 years, Zevra Therapeutics' Cash from Financing Activities had a median value of $28.5 million in 2023 and averaged $39.6 million.
  • In the last 5 years, Zevra Therapeutics' Cash from Financing Activities spiked by 4,029.57% in 2021 and then slumped by 92.62% in 2022.
  • Zevra Therapeutics' Cash from Financing Activities (Yearly) stood at $2.7 million in 2020, then skyrocketed by 4,029.57% to $113.1 million in 2021, then plummeted by 92.62% to $8.4 million in 2022, then soared by 240.80% to $28.5 million in 2023, then surged by 188.46% to $82.1 million in 2024.